- Review
- Open access
- Published:
Insights into RNA N6-methyladenosine and programmed cell death in atherosclerosis
Molecular Medicine volume 30, Article number: 137 (2024)
Abstract
N6-methyladenosine (m6A) modification stands out among various RNA modifications as the predominant form within eukaryotic cells, influencing numerous cellular processes implicated in disease development. m6A modification has gained increasing attention in the development of atherosclerosis and has become a research hotspot in recent years. Programmed cell death (PCD), encompassing apoptosis, autophagy, pyroptosis, ferroptosis, and necroptosis, plays a pivotal role in atherosclerosis pathogenesis. In this review, we delve into the intricate interplay between m6A modification and diverse PCD pathways, shedding light on their complex association during the onset and progression of atherosclerosis. Clarifying the relationship between m6A and PCD in atherosclerosis is of great significance to provide novel strategies for cardiovascular disease treatment.
Introduction
N6-methyladenosine (m6A) (see Glossary), a methylation modification of the sixth adenine (A) nitrogen, is one of the most common markers of post-transcriptional regulation that occurs in different types of RNAs, particularly in eukaryotic mRNAs (Niu et al. 2013). Recent studies have shown that m6A plays a catalytic role in the development of atherosclerosis, which is the cause of a majority of cardiovascular events. For example, m6A methyltransferase-like protein 14 (METTL14) can promote atherosclerosis via endothelial and macrophage inflammation, respectively (Dong et al. 2021; Jian et al. 2020; Zheng et al. 2022).
Programmed cell death (PCD), which includes classical apoptosis, autophagy, pyroptosis, ferroptosis and necroptosis, etc. is a subset of regulated cell death. PCD responds to internal or external threats in a positively regulated manner and is essential for maintaining normal cell cycle and tissue homeostasis (Kist and Vucic 2021; Bedoui et al. 2020). Mounting evidence has been accumulating that PCD plays a fundamental role in the development of atherosclerosis by lysing and effectively eliminating inflammatory cells (Paone et al. 2019; Pi et al. 2021; Wu et al. 2018).
As the most common epigenetic modification on RNA, m6A methylation affects RNA metabolism and thus controls PCD progression in a post-transcriptional manner. In this review, we focus on the current associations between m6A and different types of PCD pathways in the occurrence and development of atherosclerosis. We also highlight the potential diagnostic and therapeutic value of the m6A and PCD pathways in atherosclerosis.
Molecular compositions of m6A methylation
The m6A methyltransferase (writers), binding protein (readers) and demethylase (erasers) are involved in the initiation, recognition and removal of RNAs, respectively (Fig. 1). m6A modification is regulated by the m6A methylase complex, which consists of METTL3, METTL14, Wilms tumor-associated protein (WTAP), RNA-binding motif protein 15 (RBM15), etc. (Zaccara et al. 2019; Shi et al. 2019). Among them, METTL3 and METTL14 are the major catalytic cores, and their methyltransferase domains have catalytic activity (Liu et al. 2014; Wang et al. 2016). WTAP stabilizes the METTL3-METTL14 complex and promotes the RNA-binding ability of m6A methyltransferase (Ping et al. 2014; Schöller et al. 2018). RBM15 can interact with METTL3 in a WTAP-dependent manner to recruit the complex to methylate specific sites (Patil et al. 2016). However, the molecular function of other m6A writers in the m6A methylase complex remains unknown, such as Vir like m6A methyltransferase associated (VIRMA, also known as KIAA1429).
m6A modification regulators. m6A is incorporated into mRNAs in the nucleus by the methyltransferase complex, which includes proteins such as METTL3, METTL14, WTAP, RBM5/15, KIAA1429, etc. The methyl group can be removed by demethylases, including FTO and ALKBH5. RNA incorporating m6A can be recognized by readers such as YTHDC1, YTHDC2, YTHDF1, YTHDF2, YTHDF3 and IGF2BP1/2/3. m6A is involved in almost the entire process on mRNA, including splicing, translation, export, stabilisation, degradation. etc
In response to external forces, m6A modification is selectively recognized by several RNA-binding proteins (RBPs), triggering a series of downstream biological responses. YTH domain containing 1 (YTHDC1) bind m6A-modified mRNAs, and promotes RNA processing and export (Roundtree et al. 2017; Chen et al. 2021; Liang et al. 2022). Meanwhile, YTHDC2 can improve the incidence of translation of target mRNA by binding m6A-modified RNAs (Ma et al. 2021; Yuan et al. 2022). The YTH domain family protein family (YTHDF) is also m6A readers, which includes three paralogs, YTHDF1, YTHDF2, and YTHDF3. YTHDF1 enhances mRNA translation (Yuan et al. 2022), YTHDF2 promotes mRNA degradation (Li et al. 2020; Hou et al. 2021), and YTHDF3 enhances both translation and degradation (Liao et al. 2022; Chang et al. 2020). Similarly, insulin-like growth factor 2 mRNA binding proteins (IGF2BP1/2/3) promote m6A-modified mRNA stabilization and protein translation (Huang et al. 2018; Sun et al. 2022; He et al. 2022). As a dynamic reversible RNA modification, m6A can be demethylated by erasers. Fat mass and obesity-associated protein (FTO) and alkB homolog 5 (ALKBH5) have been identified as m6A erasers (Xu et al. 2020; Chen et al. 2019; Mathiyalagan et al. 2019). It should be noted that these m6A regulators are not independent components, they all maintain the balance of m6A methylation of RNA in a sophisticated manner.
Function of m6A methylation on RNA metabolism
m6A methylation is involved in mRNA metabolism, which includes mRNA splicing, translation, nuclear export, decay, etc. (Roundtree et al. 2017; Zhou et al. 2019; Wu et al. 2021; Zhang et al. 2022a, b, c) In mRNA sequences, transcripts carry m6A modifications mainly around 3’-UTR or 5’-UTR, and coding sequences (CDS) (Berulava et al. 2020). Of these, approximately 41.9% were distributed in the UTRs and 50.9% in the coding region (Meyer et al. 2012). Different locations of m6A methylation sites can lead to complex effects on the mRNA. In particular, most transcripts with methylation in the 3’-UTR are associated with metabolic processes, whereas transcripts containing m6A in the 5’-UTR or CDS are associated with energy metabolism, mitochondrial function, and intracellular pathways (Berulava et al. 2020; Kasowitz et al. 2018; Zhou et al. 2015). However, the detailed mechanism still needs to be further investigated.
In recent years, studies have shown that m6A modification is also an indispensable part of the processing of non-coding RNAs (ncRNAs), which are divided into three categories, long non-coding RNAs (lncRNAs), microRNAs (miRNAs), and circular RNAs (circRNAs) (Slack and Chinnaiyan 2019). Interestingly, not only m6A methylation regulate various aspects of ncRNAs biology, but ncRNAs also regulate the level of m6A methylation modification by altering the m6A modification regulators. For example, the lncRNA SNHG4 decreases the m6A level of STAT2 mRNA by inhibiting METTL3 expression (Li et al. 2021).
m6A modification and PCD in atherosclerosis
M6A modification was first identified in apoptosis, and then more and more studies have demonstrated that m6A regulators could interact with almost all types of PCD pathways. Here, we mainly discuss the relationship between m6A and cell apoptosis, autophagy, pyroptosis, and necroptosis in the occurrence and development of atherosclerosis (Table 1).
Apoptosis
Apoptosis occurs throughout all stages of atherosclerosis. METTL3 gene mediated Niemann-Pick C1-like protein 1 (NPC1L1) mRNA hypermethylation facilitates atherosclerosis progression through endothelial cell apoptosis (Zhang et al. 2023a, b). Zhu et al. found that METTL3 is also the major contributor to HCMV-induced apoptosis of vascular endothelial cells (Zhu et al. 2022). Mechanically, METTL3 promotes the incorporation of YTHDF3 into methylated calcium uniporter (MCU) mRNA, then increases MCU translation and expression, and thereby enhancing HCMV-induced apoptosis of vascular endothelial cells. Further analysis showed that ALKBH5 was the demethylase of MCU mRNA, which could negatively regulate the m6A modification process of MCU. Reduction of METTL14 has been reported to reduce ox-LDL-induced endothelial cell apoptosis and aortic plaque area in ApoE−/− mice treated with a high-fat diet (Liu et al. 2022). Epigenetically, METTL14-mediated m6A methylation regulated the protein expressions of bax and cleaved caspase-3 through influences p65 stability and its expression. In addition to the writer protein, the eraser protein also plays an important role. The results observed by Zhang et al. indicated that ALKBH5 overexpression inhibited the apoptosis in TNF-α-treated HUVECs by promoting the expression of Bcl-2 (Zhang et al. 2022a, b, c). Meanwhile, ALKBH5 overexpression also increased the level of pri-miR-7 and decreased the level of miR-7. MiR-7 was reported to significantly inhibit the expression of Bcl-2 (Zhu et al. 2019). These results expand the understanding of the progression mechanism of atherosclerosis and provide a potential strategy for the protection of vascular endothelial injury (Fig. 2). However, m6A-mediated apoptosis of other atherosclerotic cells, such as macrophages and vascular smooth muscle cells (VSMCs), may have additional effects that remain to be discovered .
m6A modification and apoptosis in atherosclerosis. METTL3-mediated NPC1L1 mRNA hypermethylation facilitates atherosclerosis progression by regulating the MAPK pathway. METTL3 and YTHDF3-mediated m6A methylation induces vascular endothelial cell apoptosis by promote increased MCU translation; ALKBH5 reverses METTL3-mediated m6A modification of MCU mRNA; METTL14 is involved in endothelial cell apoptosis and plaque development by regulating m6A modification of p65; ALKBH5 promoted the expression of Bcl-2 in HUVEC apoptosis; Meanwhile, ALKBH5 regulates Bcl-2 expression by decreasing the level of miR-7
Autophagy
Autophagy is an essential PCD mechanism through frequent changes in autophagy-related proteins and transcription factors (Mizushima et al. 2011). Autophagy plays an important role in the degradation of proteins and damaged organelles, and autophagy dysfunction in vascular cells is closely associated with atherosclerosis (Grootaert et al. 2018; Sergin and Razani 2014). Since the relationship between autophagy and m6A was first studied in 2018, its role in the occurrence and development of atherosclerosis has been further explored (Fig. 3A). Jin et al. performed a screen by using small interfering RNAs targeting genes encoding the writers, erasers, and readers proteins and identified the FTO protein as a positive regulator of autophagy (Jin et al. 2018). FTO can directly abrogate the m6A distribution in Unc-51 like autophagy activating kinase (ULK1), thereby reducing its degradation by YTHDF2 and further promoting the production of ULK1 protein and LC3BII (Jin et al. 2018). ULK1 plays a central role in the initiation of autophagy, a process that contributes to atherosclerosis (Ouyang et al. 2021a, b; Luo et al. 2017). m6A has also been implicated as an autophagy activator in the study of VSMCs. Enhanced METTL3 promotes autophagosome formation by upregulating the expression of autophagy-related proteins 5 and 7 (ATG5 or ATG7), and further inhibits VSMC migration and synthetic phenotype formation (Fang et al. 2023). In addition, knockout of ATG5 or ATG7 largely reversed the regulatory effect of METTL3 overexpression on the phenotypic transformation of HASMCs, as manifested by increased proliferation and migration and a preference for synthetic phenotypes (Fang et al. 2023). The proliferation of VSMCs may be beneficial throughout atherogenesis, and not only in advanced lesions (Bennett et al. 2016). The experimental results that both writer protein METTL3 and the eraser protein FTO promote autophagy are apparently contradictory. The reason may be that overexpression of FTO eliminated m6A levels in ULK1 transcripts and simultaneously reduced YTHDF2-mediated mRNA decay. These results suggest that the m6A modifier acts as a double-edged sword in autophagy, which is likely to depend on abundant RNA-binding proteins and their recognition locations. However, despite the growing recognition of the biological significance of m6A modification, the overall influence of m6A regulators on the transcription and translation of other autophagy-related genes in the development of atherosclerosis remains poorly understood. Meanwhile, whether autophagy can regulate m6A components is also worthy of further exploration.
m6A modification and autophagy, pyroptosis, ferroptosis and necroptosis in atherosclerosis. (A) m6A modification and autophagy. FTO eliminates the m6A modification of ULK1, reduces its degradation by YTHDF2 and promotes the production of LC3BII; METTL3 promotes autophagosome formation by upregulating ATG5 and ATG7 expression. (B) m6A modification and pyroptosis. METTL3 promotes macrophage pyroptosis by increasing lncRNA MALAT1 m6A methylation and decreasing hsa_circ_0029589 expression; YTHDC1 regulates the methylation of DRP1 promoter by inducing the degradation of LncRNA FENDRR, which further promotes endothelial cell pyroptosis. (C) m6A modification and ferroptosis. METTL3-YTHDF2 promoted alveolar epithelial cell ferroptosis through mediated m6A modification of GPX4; METTL3-SLC7A11/FSP1 axis regulates HASMC ferroptosis. (D) m6A modification and necroptosis. WTAP regulates T-cell necroptosis by disrupting the stability of RIPK1 mRNA; ALKBH5 promotes atherosclerosis by regulating the binding of HIF-1α to MIAT in human endothelium and monocytes; IGF2BP3 regulates HIF-1α expression by directly binding to a specific m6A site
Pyroptosis
Pyroptosis is a pro-inflammatory form of regulated cell death characterized by cell swelling, the protrusion of large bubbles from the plasma membrane and cell lysis (Xu et al. 2018). This death pathway is mediated by gasdermin D (GSDMD) pore formation, which is activated by caspase-1, and followed by the release of both cell contents and pro-inflammatory cytokines, which play a prominent role in the development of atherosclerosis, particularly in unstable atherosclerotic lesions (He et al. 2021). The involvement of METTL3-mediated m6A modification in the pyroptosis of pro-inflammatory macrophages has recently been reported. Upregulation of METTL3 increases lncRNA MALAT1 levels through m6A methylation, promotes degradation of ubiquitin specific peptidase 8 (USP8) mRNA, and then promotes pyroptosis and inflammation of macrophages (Shu et al. 2021). IFN regulatory factor (IRF)-1 is considered to be a potent activator of macrophage pyroptosis and inflammation (Dai et al. 2022). The latest studies have elucidated that IRF-1 inhibits the expression of hsa_circ_0029589 by inducing m6A levels and METTL3 expression, thereby promoting macrophages pyroptosis and inflammatory response in atherosclerosis (Guo et al. 2020). Meanwhile, the m6A reader YTHDC1 has also been reported to play an important role in the degradation of m6A-modified LncRNA FENDRR (Wang et al. 2022). m6A-induced LncRNA FENDRR degradation promotes endothelial cells pyroptosis by regulating the methylation of the dynamin-related protein 1 (DRP1) promoter (Wang et al. 2022). In conclusion, these implications crucially build a bridge between m6A and pyroptosis-related components in the development of atherosclerosis (Fig. 3B). However, more research is warranted to explore other RNAs with m6A modifications in pyroptosis.
Ferroptosis
Ferroptosis is an iron-dependent form of necrosis characterized by oxidative damage to phospholipids, which causes damage to vascular endothelial cells, macrophages and VSMCs etc. and affects many risk factors or pathological processes of atherosclerosis (Ouyang et al. 2021a, b). Recent studies have revealed the association between m6A and ferroptosis (Fig. 3C). Neutrophil extracellular traps (NETs) have been shown to promote atherosclerotic plaque formation through a pro-inflammatory immune response (Döring et al. 2017). In sepsis, NETs promote ferroptosis through METTL3-induced m6A modification of GPX4 (Zhang et al. 2022a, b, c). In contrast, METTL3 knockout inhibited NETs-induced cell ferroptosis and protected mice against sepsis-associated acute lung injury (Zhang et al. 2022a, b, c). Additionally, METTL3 overexpression has also been shown to promote ferroptosis in HASMCs by inhibiting the expression of key ferroptosis regulatory proteins, such as solute carrier family 7 member 11 (SLC7A11) and ferroptosis suppressor protein 1 (FSP1) (Li et al. 2022). Overexpression of SLC7A11 or FSP1 largely rescues the effect of METTL3 on ferroptosis in HASMC (Li et al. 2022). These studies have linked m6A to ferroptosis and indirectly support the role of METTL3 modification-induced ferroptosis in the development of atherosclerosis. Targeting METTL3 can be used as a potential motivator of ferroptosis in atherosclerotic patients to guide clinical treatment.
Necroptosis
Necroptosis, a novel pro-inflammatory programmed cell death pathway characterised by early loss of cytoplasmic membrane integrity, leakage of cell contents, and organelles swelling, has been implicated in atherosclerosis (Coornaert et al. 2018; Gao et al. 2022). Two kinase proteins that play pivotal roles in the necroptosis pathway, receptor-interacting protein kinase 1 (RIPK1) and RIPK3, have emerged as the key proteins for their destructive role in atherosclerosis (DeRoo et al. 2020). Recent studies have shown that WTAP, one of the key proteins in the function of the m6A methyltransferase complex, destabilises RIPK1 mRNA and further regulates T-cell necroptosis (Ito-Kureha et al. 2022). These findings uncover a potential pathway by which m6A modifications affect cell necroptosis. Hypoxia-inducible factor (HIF)-1α has been shown to promote macrophage necroptosis by regulating miR-210 and miR-383 (Karshovska et al. 2020). Wu et al. demonstrated that ox-LDL-induced ALKBH5 promoted HIF-1α binding and activating myocardial infarction-associated transcript (MIAT) in human endothelium and monocytes, which further promoted atherosclerosis progression (Wu et al. 2019). Further studies revealed that the m6A reader insulin-like growth factor-II mRNA-binding protein 3 (IGF2BP3) positively regulated HIF-1α expression by directly binding to a specific m6A site in the coding region of HIF-1α mRNA (Jiang et al. 2021). Taken together, these results support the possibility that m6A modifications are actively involved in necroptosis in the development of atherosclerosis (Fig. 3D). However, direct evidence for m6A-mediated necroptosis needs to be further investigated.
Clinical application of the target-based m6A-PCD axis in atherosclerosis
Emerging data indicate that the abnormal global abundance of m6A, abnormal gene expression levels of m6A writers, erasers and readers, and m6A site mutations are common in various diseases, providing promising biomarkers for clinical diagnosis and treatment. m6A modification-related proteins have multiple functions in PCD, and elucidating their interaction in the pathological process is helpful in discovering specific potential biomarkers and therapeutic targets, providing a strong basis for the diagnosis and treatment of atherosclerosis. In particular, by focusing on the association of m6A with apoptosis, autophagy, ferroptosis and necroptosis of vascular cells in atherosclerosis, we cannot ignore the potential value of m6A in anti-atherosclerosis. In conclusion, the m6A-mediated PCD axis has become an important mechanism in the pathological process. Meanwhile, RNA contains multiple m6A sites in the PCD pathway, and targeting multiple m6A sites shows more diagnostic and therapeutic potential than targeting a single m6A.
Diagnostic potential
Zhou et al. identified the pathological model of human coronary artery smooth muscle cells (HCASMCs) induced in vitro by RNA-Seq and meRIP-Seq, and identified 5121 m6A peaks and 883 mRNAs differentially expressed in the pathological process of HCASMCs (Zhou et al. 2022a, b). Among them, METTL3 is up-regulated in atherosclerotic lesions and HCASMCs proliferation and migration models, and METTL3 knockdown can inhibit the pathological process of HCASMCs. Meanwhile, the expression of peripheral blood mononuclear cell-derived macrophage RNA in patients with coronary artery disease was detected by RNA-Seq, and the expression level of METTL3 was significantly increased. Upregulation of METTL3 can significantly increase the expression of hsa_circ_0029589, and promote macrophage pyroptosis and inflammatory response in atherosclerosis (Guo et al. 2020). These findings may contribute to the expansion of METTL3 as a potential diagnostic marker for atherosclerosis (Table 2). However, other m6A-modified proteins are currently lacking in animal and clinical trials, and their diagnostic effect on atherosclerosis is still not perfect, which deserves further investigation in the future.
Therapeutic potential
METTL3 is one of the major m6A modified proteins most commonly reported to be associated with the development of atherosclerosis. Upregulated METTL3 increases the m6A level of NLRP3 mRNA, leading to the release of pro-inflammatory cytokines from macrophages. Moreover, miR-1208 can inhibit the expression of NLRP3 and lead to decreased release of inflammatory cytokines after targeted binding to METTL3, suggesting that miR-1208 and its downstream gene METTL3 are potential targets for the prevention and treatment of atherosclerosis (Zhou et al. 2022a, b). Vitamin D3 is a multifunctional fat-soluble hormone that is essential in atherosclerosis (Lu et al. 2020; Bobryshev 2010). Recent studies have shown that vitamin D3 downregulates METTL3 by inhibiting AMPK activation, thereby inhibiting m6A modification and apoptosis of vascular endothelial cells (Zhu et al. 2022). This finding adds to the understanding of the m6A driving mechanism in vascular endothelial injury and highlights the significance of METTL3 in the intervention of atherosclerosis. In addition, inhibition of FTO is closely related to anti-atherosclerosis by regulating the PCD pathway. In Luo et al.‘s study, nanoparticle-mediated delivery of FTO-siRNA or administration of the FTO inhibitor entacapone inhibited lipopolysaccharide-induced macrophage pyroptosis (Luo et al. 2021). Mechanistically, ablation of FTO inhibits the NLRP3 inflammasome in macrophages through the forkhead box protein O1/nuclear factor kappa-B (FOXO1/ NF-κB) signalling pathway. Accordingly, inhibition of FTO is expected to be used in the treatment of atherosclerosis. It is well known that impaired blood flow and associated oscillatory stress (OS) play a central role in the development of atherosclerosis. Chien et al. investigated the role of m6A methylation in mechanical transduction of endothelial cells (ECs) (Chien et al. 2021). They have determined that OS causes hypermethylation of m6A RNA, in which the m6A methyltransferase METTL3 is the center of response to hemodynamic and atherogenic stimuli in ECs. Further RNA sequencing and m6A enhanced cross-linking and immunoprecipitation (eCLIP) experiments showed that NLRP3 is a hemodynamically related downstream target of METTL3-mediated hypermethylation, recognized by the m6A reader protein YTHDF1. In the vivo atherosclerosis model, repeated administration of METTL3 shRNA prevented the atherogenic process and the upregulation of NLRP3. Together, these results support the clinical therapeutic potential of the m6A-PCD axis in the development and progression of atherosclerosis (Table 3). In the near future, specific m6A- modified targeted drugs may be developed and used in preclinical and clinically validated treatment of atherosclerosis.
Concluding remarks and future perspectives
A large number of studies have confirmed that m6A modification is an important target for the treatment of atherosclerosis and that improving m6A level can effectively reduce the progression of atherosclerosis (Yang et al. 2023; Zhang et al. 2023a, b; Yu et al. 2022). A High-fat diet is a major cause of atherosclerosis. Evidence suggests that maternal consumption of a high-fat diet increases m6A modification in offspring, which can lead to elevated triglycerides and altered pro-inflammatory profiles in adult offspring (Izquierdo et al. 2021). These findings have prompted researchers to investigate the role of m6A in atherosclerosis.
In this review, we summarize the potential function of m6A methylation in PCD, particularly in the context of atherosclerosis. In addition, we highlight the promise of diagnostics and therapies based on interference with m6A in PCD, which could have a transformative impact on clinical medicine. However, the current understanding of the relationship between the m6A-PCD axis and atherosclerosis is only the tip of the iceberg. Objectively speaking, some of the functions of m6A in PCD are inferred from the known studies involving this mRNA modification. Despite recent progress, many challenging problems remain in fully understanding the specific mechanisms of m6A and PCD in the development of atherosclerosis (see Outstanding questions). Further research is urgently needed to explore in depth.
Firstly, a plethora of unexplored m6A regulators in programmed cell death (PCD) awaits discovery, including YTHDF1, YTHDF1, YTHDC1, YTHDC2, and others. Secondly, the investigation into m6A-mediated PCD within atherosclerosis-associated cells, such as macrophages and vascular smooth muscle cells (VSMCs), remains limited, potentially harboring undiscovered effects. Thirdly, m6A regulatory factors encompass inhibitors of the METTL3-METTL14 complex (3-deazaadenosine, eltrombopag) (Feng et al. 2022; Yankova et al. 2021; Buker et al. 2020), and FTO inhibitors (FB23-2, entacarone) (Huang et al. 2019; Peng et al. 2019). Whether these compounds precisely modulate atherosclerosis by controlling PCD pathways remains elusive. Fourthly, the crosstalk between different PCDs with a particular m6A modification enzyme still needs to be further investigated. Lastly, the interaction between different epigenetic modifications on PCD in atherosclerosis has not been studied.
We believe that the development of m6A-PCD axis-related targeted therapies in atherosclerosis will be a focus in the near future. Currently, targeting m6A via the writing enzyme METTL3 or the erasing enzyme FTO appears to be the most promising new therapy in atherosclerosis. With existing technological advances, targeted therapy for atherosclerosis based on the m6A-PCD axis will provide more options for cardiologists. The rewards would be enormous if we could use the m6A-PCD axis to predict and intervene in the progression of atherosclerosis.
Data availability
No datasets were generated or analysed during the current study.
References
Bedoui S, Herold MJ, Strasser A. Emerging connectivity of programmed cell death pathways and its physiological implications. Nat Rev Mol Cell Biol. 2020;21:678–95.
Bennett MR, Sinha S, Owens GK. Vascular smooth muscle cells in atherosclerosis. Circ Res. 2016;118:692–702.
Berulava T, Buchholz E, Elerdashvili V, Pena T, Islam MR, Lbik D, Mohamed BA, Renner A, von Lewinski D, Sacherer M, Bohnsack KE, Bohnsack MT, Jain G, Capece V, Cleve N, Burkhardt S, Hasenfuss G, Fischer A, Toischer K. Changes in m6a rna methylation contribute to heart failure progression by modulating translation. Eur J Heart Fail. 2020;22:54–66.
Bobryshev YV. Vitamin d3 suppresses immune reactions in atherosclerosis, affecting regulatory t cells and dendritic cell function. Arterioscler Thromb Vasc Biol. 2010;30:2317–9.
Buker SM, Gurard-Levin ZA, Wheeler BD, Scholle MD, Case AW, Hirsch JL, Ribich S, Copeland RA, Boriack-Sjodin PA. A mass spectrometric assay of mettl3/mettl14 methyltransferase activity. SLAS Discov. 2020;25:361–71.
Chang G, Shi L, Ye Y, Shi H, Zeng L, Tiwary S, Huse JT, Huo L, Ma L, Ma Y, Zhang S, Zhu J, Xie V, Li P, Han L, He C, Huang S. Ythdf3 induces the translation of m(6)a-enriched gene transcripts to promote breast cancer brain metastasis. Cancer Cell. 2020;38:857–71. .e857.
Chen XY, Zhang J, Zhu JS. The role of m(6)a rna methylation in human cancer. Mol Cancer. 2019;18:103.
Chen C, Liu W, Guo J, Liu Y, Liu X, Liu J, Dou X, Le R, Huang Y, Li C, Yang L, Kou X, Zhao Y, Wu Y, Chen J, Wang H, Shen B, Gao Y, Gao S. Nuclear m(6)a reader ythdc1 regulates the scaffold function of line1 rna in mouse escs and early embryos. Protein Cell. 2021;12:455–74.
Chien CS, Li JY, Chien Y, Wang ML, Yarmishyn AA, Tsai PH, Juan CC, Nguyen P, Cheng HM, Huo TI, Chiou SH, Chien S. Mettl3-dependent n(6)-methyladenosine rna modification mediates the atherogenic inflammatory cascades in vascular endothelium. Proc Natl Acad Sci U S A. 2021;118.
Coornaert I, Hofmans S, Devisscher L, Augustyns K, Van Der Veken P, De Meyer GRY, Martinet W. Novel drug discovery strategies for atherosclerosis that target necrosis and necroptosis. Expert Opin Drug Discov. 2018;13:477–88.
Dai M, Li Q, Pan P. The modulation of interferon regulatory factor-1 via caspase-1-mediated alveolar macrophage pyroptosis in ventilator-induced lung injury. Mediators Inflamm. 2022;2022:1002582.
DeRoo E, Zhou T, Liu B. The role of ripk1 and ripk3 in cardiovascular disease. Int J Mol Sci. 2020;21.
Dong G, Yu J, Shan G, Su L, Yu N, Yang S. N6-methyladenosine methyltransferase mettl3 promotes angiogenesis and atherosclerosis by upregulating the jak2/stat3 pathway via m6a reader igf2bp1. Front Cell Dev Biol. 2021;9:731810.
Döring Y, Soehnlein O, Weber C. Neutrophil extracellular traps in atherosclerosis and atherothrombosis. Circ Res. 2017;120:736–43.
Fang ZM, Zhang SM, Luo H, Jiang DS, Huo B, Zhong X, Feng X, Cheng W, Chen Y, Feng G, Wu X, Zhao F, Yi X. Methyltransferase-like 3 suppresses phenotypic switching of vascular smooth muscle cells by activating autophagosome formation. Cell Prolif. 2023;56:e13386.
Feng Z, Zhou F, Tan M, Wang T, Chen Y, Xu W, Li B, Wang X, Deng X, He ML. Targeting m6a modification inhibits herpes virus 1 infection. Genes Dis. 2022;9:1114–28.
Gao W, Wang X, Zhou Y, Wang X, Yu Y. Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy. Signal Transduct Target Ther. 2022;7:196.
Grootaert MOJ, Moulis M, Roth L, Martinet W, Vindis C, Bennett MR, De Meyer GRY. Vascular smooth muscle cell death, autophagy and senescence in atherosclerosis. Cardiovasc Res. 2018;114:622–34.
Guo M, Yan R, Ji Q, Yao H, Sun M, Duan L, Xue Z, Jia Y. Ifn regulatory factor-1 induced macrophage pyroptosis by modulating m6a modification of circ_0029589 in patients with acute coronary syndrome. Int Immunopharmacol. 2020;86:106800.
He X, Fan X, Bai B, Lu N, Zhang S, Zhang L. Pyroptosis is a critical immune-inflammatory response involved in atherosclerosis. Pharmacol Res. 2021;165:105447.
He M, Lei H, He X, Liu Y, Wang A, Ren Z, Liu X, Yan G, Wang W, Wang Y. Mettl14 regulates osteogenesis of bone marrow mesenchymal stem cells via inducing autophagy through m6a/igf2bps/beclin-1 signal axis. Stem Cells Translational Med. 2022;11:987–1001.
Hou G, Zhao X, Li L, Yang Q, Liu X, Huang C, Lu R, Chen R, Wang Y, Jiang B, Yu J. Sumoylation of ythdf2 promotes mrna degradation and cancer progression by increasing its binding affinity with m6a-modified mrnas. Nucleic Acids Res. 2021;49:2859–77.
Huang H, Weng H, Sun W, Qin X, Shi H, Wu H, Zhao BS, Mesquita A, Liu C, Yuan CL, Hu YC, Hüttelmaier S, Skibbe JR, Su R, Deng X, Dong L, Sun M, Li C, Nachtergaele S, Wang Y, Hu C, Ferchen K, Greis KD, Jiang X, Wei M, Qu L, Guan JL, He C, Yang J, Chen J. Recognition of rna n(6)-methyladenosine by igf2bp proteins enhances mrna stability and translation. Nat Cell Biol. 2018;20:285–95.
Huang Y, Su R, Sheng Y, Dong L, Dong Z, Xu H, Ni T, Zhang ZS, Zhang T, Li C, Han L, Zhu Z, Lian F, Wei J, Deng Q, Wang Y, Wunderlich M, Gao Z, Pan G, Zhong D, Zhou H, Zhang N, Gan J, Jiang H, Mulloy JC, Qian Z, Chen J, Yang CG. Small-molecule targeting of oncogenic fto demethylase in acute myeloid leukemia. Cancer Cell. 2019;35:677–91. .e610.
Ito-Kureha T, Leoni C, Borland K, Cantini G, Bataclan M, Metzger RN, Ammann G, Krug AB, Marsico A, Kaiser S, Canzar S, Feske S, Monticelli S, König J, Heissmeyer V. The function of wtap in n(6)-adenosine methylation of mrnas controls t cell receptor signaling and survival of t cells. Nat Immunol. 2022;23:1208–21.
Izquierdo V, Palomera-Ávalos V, Pallàs M, Griñán-Ferré C. Resveratrol supplementation attenuates cognitive and molecular alterations under maternal high-fat diet intake: epigenetic inheritance over generations. Int J Mol Sci. 2021;22.
Jian D, Wang Y, Jian L, Tang H, Rao L, Chen K, Jia Z, Zhang W, Liu Y, Chen X, Shen X, Gao C, Wang S, Li M. Mettl14 aggravates endothelial inflammation and atherosclerosis by increasing foxo1 n6-methyladeosine modifications. Theranostics. 2020;10:8939–56.
Jiang L, Li Y, He Y, Wei D, Yan L, Wen H. Knockdown of m6a reader igf2bp3 inhibited hypoxia-induced cell migration and angiogenesis by regulating hypoxia inducible factor-1α in stomach cancer. Front Oncol. 2021;11:711207.
Jin S, Zhang X, Miao Y, Liang P, Zhu K, She Y, Wu Y, Liu DA, Huang J, Ren J, Cui J. M(6)a rna modification controls autophagy through upregulating ulk1 protein abundance. Cell Res. 2018;28:955–7.
Karshovska E, Wei Y, Subramanian P, Mohibullah R, Geißler C, Baatsch I, Popal A, Corbalán Campos J, Exner N, Schober A. Hif-1α (hypoxia-inducible factor-1α) promotes macrophage necroptosis by regulating mir-210 and mir-383. Arterioscler Thromb Vasc Biol. 2020;40:583–96.
Kasowitz SD, Ma J, Anderson SJ, Leu NA, Xu Y, Gregory BD, Schultz RM, Wang PJ. Nuclear m6a reader ythdc1 regulates alternative polyadenylation and splicing during mouse oocyte development. PLoS Genet. 2018;14:e1007412.
Kist M, Vucic D. Cell death pathways: intricate connections and disease implications. Embo j. 2021;40:e106700.
Li J, Xie H, Ying Y, Chen H, Yan H, He L, Xu M, Xu X, Liang Z, Liu B, Wang X, Zheng X, Xie L. Ythdf2 mediates the mrna degradation of the tumor suppressors to induce akt phosphorylation in n6-methyladenosine-dependent way in prostate cancer. Mol Cancer. 2020;19:152.
Li SX, Yan W, Liu JP, Zhao YJ, Chen L. Long noncoding rna snhg4 remits lipopolysaccharide-engendered inflammatory lung damage by inhibiting mettl3 - mediated m(6)a level of stat2 mrna. Mol Immunol. 2021;139:10–22.
Li N, Yi X, He Y, Huo B, Chen Y, Zhang Z, Wang Q, Li Y, Zhong X, Li R, Zhu XH, Fang Z, Wei X, Jiang DS. Targeting ferroptosis as a novel approach to alleviate aortic dissection. Int J Biol Sci. 2022;18:4118–34.
Liang D, Lin WJ, Ren M, Qiu J, Yang C, Wang X, Li N, Zeng T, Sun K, You L, Yan L, Wang W. M(6)a reader ythdc1 modulates autophagy by targeting sqstm1 in diabetic skin. Autophagy. 2022;18:1318–37.
Liao L, He Y, Li SJ, Zhang GG, Yu W, Yang J, Huang ZJ, Zheng CC, He QY, Li Y, Li B. Anti-hiv drug elvitegravir suppresses cancer metastasis via increased proteasomal degradation of m6a methyltransferase mettl3. Cancer Res. 2022;82:2444–57.
Liu J, Yue Y, Han D, Wang X, Fu Y, Zhang L, Jia G, Yu M, Lu Z, Deng X, Dai Q, Chen W, He C. A mettl3-mettl14 complex mediates mammalian nuclear rna n6-adenosine methylation. Nat Chem Biol. 2014;10:93–5.
Liu Y, Luo G, Tang Q, Song Y, Liu D, Wang H, Ma J. Methyltransferase-like 14 silencing relieves the development of atherosclerosis via m(6)a modification of p65 mrna. Bioengineered. 2022;13:11832–43.
Lu YW, Chou RH, Liu LK, Chen LK, Huang PH, Lin SJ. The relationship between circulating vitamin d3 and subclinical atherosclerosis in an elderly Asian population. Sci Rep. 2020;10:18704.
Luo Z, Xu W, Ma S, Qiao H, Gao L, Zhang R, Yang B, Qiu Y, Chen J, Zhang M, Tao B, Cao F, Wang Y. Moderate autophagy inhibits vascular smooth muscle cell senescence to stabilize progressed atherosclerotic plaque via the mtorc1/ulk1/atg13 signal pathway. Oxid Med Cell Longev. 2017;2017:3018190.
Luo J, Wang F, Sun F, Yue T, Zhou Q, Yang C, Rong S, Yang P, Xiong F, Yu Q, Zhang S, Wang CY, Li J. Targeted inhibition of fto demethylase protects mice against lps-induced septic shock by suppressing nlrp3 inflammasome. Front Immunol. 2021;12:663295.
Ma L, Chen T, Zhang X, Miao Y, Tian X, Yu K, Xu X, Niu Y, Guo S, Zhang C, Qiu S, Qiao Y, Fang W, Du L, Yu Y, Wang J. The m(6)a reader ythdc2 inhibits lung adenocarcinoma tumorigenesis by suppressing slc7a11-dependent antioxidant function. Redox Biol. 2021;38:101801.
Mathiyalagan P, Adamiak M, Mayourian J, Sassi Y, Liang Y, Agarwal N, Jha D, Zhang S, Kohlbrenner E, Chepurko E, Chen J, Trivieri MG, Singh R, Bouchareb R, Fish K, Ishikawa K, Lebeche D, Hajjar RJ, Sahoo S. Fto-dependent n(6)-methyladenosine regulates cardiac function during remodeling and repair. Circulation. 2019;139:518–32.
Meyer KD, Saletore Y, Zumbo P, Elemento O, Mason CE, Jaffrey SR. Comprehensive analysis of mrna methylation reveals enrichment in 3’ utrs and near stop codons. Cell. 2012;149:1635–46.
Mizushima N, Komatsu M, Autophagy. Renovation of cells and tissues. Cell. 2011;147:728–41.
Niu Y, Zhao X, Wu YS, Li MM, Wang XJ, Yang YG. N6-methyl-adenosine (m6a) in rna: an old modification with a novel epigenetic function. Genomics Proteom Bioinf. 2013;11:8–17.
Ouyang C, Li J, Zheng X, Mu J, Torres G, Wang Q, Zou MH, Xie Z. Deletion of ulk1 inhibits neointima formation by enhancing kat2a/gcn5-mediated acetylation of tuba/α-tubulin in vivo. Autophagy. 2021a;17:4305–22.
Ouyang S, You J, Zhi C, Li P, Lin X, Tan X, Ma W, Li L, Xie W. Ferroptosis: the potential value target in atherosclerosis. Cell Death Dis. 2021b;12:782.
Paone S, Baxter AA, Hulett MD, Poon IKH. Endothelial cell apoptosis and the role of endothelial cell-derived extracellular vesicles in the progression of atherosclerosis. Cell Mol Life Sci. 2019;76:1093–106.
Patil DP, Chen CK, Pickering BF, Chow A, Jackson C, Guttman M, Jaffrey SR. M(6)a rna methylation promotes xist-mediated transcriptional repression. Nature. 2016;537:369–73.
Peng S, Xiao W, Ju D, Sun B, Hou N, Liu Q, Wang Y, Zhao H, Gao C, Zhang S, Cao R, Li P, Huang H, Ma Y, Wang Y, Lai W, Ma Z, Zhang W, Huang S, Wang H, Zhang Z, Zhao L, Cai T, Zhao YL, Wang F, Nie Y, Zhi G, Yang YG, Zhang EE, Huang N. Identification of entacapone as a chemical inhibitor of fto mediating metabolic regulation through foxo1. Sci Transl Med. 2019;11.
Pi S, Mao L, Chen J, Shi H, Liu Y, Guo X, Li Y, Zhou L, He H, Yu C, Liu J, Dang Y, Xia Y, He Q, Jin H, Li Y, Hu Y, Miao Y, Yue Z, Hu B. The p2ry12 receptor promotes vsmc-derived foam cell formation by inhibiting autophagy in advanced atherosclerosis. Autophagy. 2021;17:980–1000.
Ping XL, Sun BF, Wang L, Xiao W, Yang X, Wang WJ, Adhikari S, Shi Y, Lv Y, Chen YS, Zhao X, Li A, Yang Y, Dahal U, Lou XM, Liu X, Huang J, Yuan WP, Zhu XF, Cheng T, Zhao YL, Wang X, Rendtlew Danielsen JM, Liu F, Yang YG. Mammalian wtap is a regulatory subunit of the rna n6-methyladenosine methyltransferase. Cell Res. 2014;24:177–89.
Roundtree IA, Luo GZ, Zhang Z, Wang X, Zhou T, Cui Y, Sha J, Huang X, Guerrero L, Xie P, He E, Shen B, He C. Ythdc1 mediates nuclear export of n(6)-methyladenosine methylated mrnas. Elife. 2017;6.
Schöller E, Weichmann F, Treiber T, Ringle S, Treiber N, Flatley A, Feederle R, Bruckmann A, Meister G. Interactions, localization, and phosphorylation of the m(6)a generating mettl3-mettl14-wtap complex. RNA. 2018;24:499–512.
Sergin I, Razani B. Self-eating in the plaque: what macrophage autophagy reveals about atherosclerosis. Trends Endocrinol Metab. 2014;25:225–34.
Shi H, Wei J, He C. Where, when, and how: context-dependent functions of rna methylation writers, readers, and erasers. Mol Cell. 2019;74:640–50.
Shu B, Zhou YX, Li H, Zhang RZ, He C, Yang X. The mettl3/malat1/ptbp1/usp8/tak1 axis promotes pyroptosis and m1 polarization of macrophages and contributes to liver fibrosis. Cell Death Discov. 2021;7:368.
Slack FJ, Chinnaiyan AM. The role of non-coding rnas in oncology. Cell. 2019;179:1033–55.
Sun C-Y, Cao D, Du B-B, Chen C-W, Liu D. The role of insulin-like growth factor 2 mrna-binding proteins (igf2bps) as m6a readers in cancer. Int J Biol Sci. 2022;18:2744.
Wang P, Doxtader KA, Nam Y. Structural basis for cooperative function of mettl3 and mettl14 methyltransferases. Mol Cell. 2016;63:306–17.
Wang X, Li Q, He S, Bai J, Ma C, Zhang L, Guan X, Yuan H, Li Y, Zhu X, Mei J, Gao F, Zhu D. Lncrna fendrr with m6A RNA methylation regulates hypoxia-induced pulmonary artery endothelial cell pyroptosis by mediating drp1 DNA methylation. Mol Med. 2022;28:126.
Wu X, Zhang H, Qi W, Zhang Y, Li J, Li Z, Lin Y, Bai X, Liu X, Chen X, Yang H, Xu C, Zhang Y, Yang B. Nicotine promotes atherosclerosis via ros-nlrp3-mediated endothelial cell pyroptosis. Cell Death Dis. 2018;9:171.
Wu L, Pei Y, Zhu Y, Jiang M, Wang C, Cui W, Zhang D. Association of n(6)-methyladenine DNA with plaque progression in atherosclerosis via myocardial infarction-associated transcripts. Cell Death Dis. 2019;10:909.
Wu R, Chen Y, Liu Y, Zhuang L, Chen W, Zeng B, Liao X, Guo G, Wang Y, Wang X. M6a methylation promotes white-to-beige fat transition by facilitating hif1a translation. EMBO Rep. 2021;22:e52348.
Xu Y-J, Zheng L, Hu Y-W, Wang Q. Pyroptosis and its relationship to atherosclerosis. Clin Chim Acta. 2018;476:28–37.
Xu K, Mo Y, Li D, Yu Q, Wang L, Lin F, Kong C, Balelang MF, Zhang A, Chen S, Dai Q, Wang J. N(6)-methyladenosine demethylases alkbh5/fto regulate cerebral ischemia-reperfusion injury. Ther Adv Chronic Dis. 2020;11:2040622320916024.
Yang Q, Chen S, Wang X, Yang X, Chen L, Huang T, Zheng Y, Zheng X, Wu X, Sun Y, Wu J. Exercise mitigates endothelial pyroptosis and atherosclerosis by downregulating neat1 through n6-methyladenosine modifications. Arterioscler Thromb Vasc Biol. 2023;43:910–26.
Yankova E, Blackaby W, Albertella M, Rak J, De Braekeleer E, Tsagkogeorga G, Pilka ES, Aspris D, Leggate D, Hendrick AG, Webster NA, Andrews B, Fosbeary R, Guest P, Irigoyen N, Eleftheriou M, Gozdecka M, Dias JML, Bannister AJ, Vick B, Jeremias I, Vassiliou GS, Rausch O, Tzelepis K, Kouzarides T. Small-molecule inhibition of mettl3 as a strategy against myeloid leukaemia. Nature. 2021;593:597–601.
Yu Z, Zheng X, Wang C, Chen C, Ning N, Peng D, Liu T, Pan W. The traditional Chinese medicine Hua Tuo Zai Zao Wan alleviates atherosclerosis by deactivation of inflammatory macrophages. Evid Based Complement Alternat Med. 2022;2022:2200662.
Yuan W, Chen S, Li B, Han X, Meng B, Zou Y, Chang S. The n6-methyladenosine reader protein ythdc2 promotes gastric cancer progression via enhancing yap mrna translation. Transl Oncol. 2022;16:101308.
Zaccara S, Ries RJ, Jaffrey SR. Reading, writing and erasing mrna methylation. Nat Rev Mol Cell Biol. 2019;20:608–24.
Zhang G, Xu Y, Wang X, Zhu Y, Wang L, Zhang W, Wang Y, Gao Y, Wu X, Cheng Y, Sun Q, Chen D. Dynamic fmr1 granule phase switch instructed by m6a modification contributes to maternal rna decay. Nat Commun. 2022a;13:859.
Zhang X, Deng S, Peng Y, Wei H, Tian Z. Alkbh5 inhibits tnf-α-induced apoptosis of huvecs through bcl-2 pathway. Open Med (Wars). 2022b;17:1092–9.
Zhang H, Liu J, Zhou Y, Qu M, Wang Y, Guo K, Shen R, Sun Z, Cata JP, Yang S, Chen W, Miao C. Neutrophil extracellular traps mediate m(6)a modification and regulates sepsis-associated acute lung injury by activating ferroptosis in alveolar epithelial cells. Int J Biol Sci. 2022c;18:3337–57.
Zhang G, Li X, Huang X. M6a-related bioinformatics analysis and functional characterization reveals that mettl3-mediated npc1l1 mrna hypermethylation facilitates progression of atherosclerosis via inactivation of the mapk pathway. Inflamm Res. 2023a;72:429–42.
Zhang Y, Wang R, Tan H, Wu K, Hu Y, Diao H, Wang D, Tang X, Leng M, Li X, Cai Z, Luo D, Shao X, Yan M, Chen Y, Rong X, Guo J. Fufang Zhenzhu Tiaozhi (ftz) capsule ameliorates diabetes-accelerated atherosclerosis via suppressing ythdf2-mediated m(6)a modification of sirt3 mrna. J Ethnopharmacol. 2023b;317:116766.
Zheng Y, Li Y, Ran X, Wang D, Zheng X, Zhang M, Yu B, Sun Y, Wu J. Mettl14 mediates the inflammatory response of macrophages in atherosclerosis through the nf-κb/il-6 signaling pathway. Cell Mol Life Sci. 2022;79:311.
Zhou J, Wan J, Gao X, Zhang X, Jaffrey SR, Qian SB. Dynamic m(6)a mrna methylation directs translational control of heat shock response. Nature. 2015;526:591–4.
Zhou KI, Shi H, Lyu R, Wylder AC, Matuszek Ż, Pan JN, He C, Parisien M, Pan T. Regulation of co-transcriptional pre-mrna splicing by m(6)a through the low-complexity protein hnrnpg. Mol Cell. 2019;76:70–81. .e79.
Zhou Y, Jiang R, Jiang Y, Fu Y, Manafhan Y, Zhu J, Jia E. Exploration of n6-methyladenosine profiles of mrnas and the function of mettl3 in atherosclerosis. Cells. 2022a;11.
Zhou H, Shen X, Yan C, Xiong W, Ma Z, Tan Z, Wang J, Li Y, Liu J, Duan A, Liu F. Extracellular vesicles derived from human umbilical cord mesenchymal stem cells alleviate osteoarthritis of the knee in mice model by interacting with mettl3 to reduce m6a of nlrp3 in macrophage. Stem Cell Res Ther. 2022b;13:322.
Zhu H, Gan X, Jiang X, Diao S, Wu H, Hu J. Alkbh5 inhibited autophagy of epithelial ovarian cancer through mir-7 and bcl-2. J Exp Clin Cancer Res. 2019;38:163.
Zhu W, Zhang H, Wang S. Vitamin d3 suppresses human cytomegalovirus-induced vascular endothelial apoptosis via rectification of paradoxical m6a modification of mitochondrial calcium uniporter mrna, which is regulated by mettl3 and ythdf3. Front Microbiol. 2022;13:861734.
Acknowledgements
The authors would like to acknowledge the Postdoctoral Station of Clinical Medicine at the Third Xiangya Hospital, Central South University for their expertise.
Funding
This study was supported by the National Natural Science Foundation of China (grant numbers 82270519, and 82200506) and the Natural Science Foundation of Hunan Province (grant numbers 2023JJ30838, 2021JJ31028).
Ethics declarations
Ethics approval and consent to participate
Not applicable.
Consent for publication
All participants were informed and gave written consent.
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Long, H., Yu, Y., Ouyang, J. et al. Insights into RNA N6-methyladenosine and programmed cell death in atherosclerosis. Mol Med 30, 137 (2024). https://doi.org/10.1186/s10020-024-00901-z
Received:
Accepted:
Published:
DOI: https://doi.org/10.1186/s10020-024-00901-z